Treatment response in CML - Chronic Myeloid Leukemia
Types of responses:
Hematologic response (HR) Complete hematologic response (CHR) Major cytogenetic response (MCR or MCyR) Complete cytogenetic response (CCR or CCyR) Major molecular response (MMR) Complete molecular response (CMR) |
Reduction of white cells Normal count of white cells 1 - 35% Ph+ cells No Ph+ cells BCR-ABL IS ≤ 0.10% no BCR-ABL detectible |
VIDEOS
Tweaking Treatments to Improve Survival
February 7, 2020, Patient Power
Mechanisms of TKI resistance
October 9, 2017, European Society for Medical Oncology
Defining Suboptimal Response to BCR-ABL TKI Therapy in CML
January 20, 2017, OncLiveTV
CML molecular monitoring: Practical advice
April 15, 2016, ImedexCME
Resistant Chronic Myeloid Leukemia
June 19, 2015, Leukemia & Lymphoma Society
Tweaking Treatments to Improve Survival
February 7, 2020, Patient Power
Mechanisms of TKI resistance
October 9, 2017, European Society for Medical Oncology
Defining Suboptimal Response to BCR-ABL TKI Therapy in CML
January 20, 2017, OncLiveTV
CML molecular monitoring: Practical advice
April 15, 2016, ImedexCME
Resistant Chronic Myeloid Leukemia
June 19, 2015, Leukemia & Lymphoma Society
ARTICLES
Leukemia Treatment Regimens: Chronic Myeloid Leukemia (CML)
February 14, 2022, Oncology Nurse Advisor
BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase
July 21, 2015, Leukemia
Dynamics Of Chronic Myeloid Leukemia Response To Dasatinib, Nilotinib, And High-Dose Imatinib
November 2014, Haematologica
Molecular response in CML: where is the bar? | Blood Journal
2014, Blood Journal
Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
2014, NCBI
European LeukemiaNet Recommendations for Management of Chronic Myeloid Leukemia
2013, PubMed
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
May 20, 2008, Blood Journal
Leukemia Treatment Regimens: Chronic Myeloid Leukemia (CML)
February 14, 2022, Oncology Nurse Advisor
BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase
July 21, 2015, Leukemia
Dynamics Of Chronic Myeloid Leukemia Response To Dasatinib, Nilotinib, And High-Dose Imatinib
November 2014, Haematologica
Molecular response in CML: where is the bar? | Blood Journal
2014, Blood Journal
Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
2014, NCBI
European LeukemiaNet Recommendations for Management of Chronic Myeloid Leukemia
2013, PubMed
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
May 20, 2008, Blood Journal
Modes of access to the website
1 - Public access
On several occasions, the CML patient called CMLer will need a password to access several modules of the website. .
(No registration required - Anonymous access)
1 - Public access
On several occasions, the CML patient called CMLer will need a password to access several modules of the website. .
(No registration required - Anonymous access)
2 - Reserved access to CMLeukemia private group
On other occasions, the more experienced patients will need more up-to-date or in-depth information. Among other upcoming modules, they will need access to the archives and also to abstracts of congresses on CML.
(Member password required and registration required).
On other occasions, the more experienced patients will need more up-to-date or in-depth information. Among other upcoming modules, they will need access to the archives and also to abstracts of congresses on CML.
(Member password required and registration required).